Print

Bio-Path Holdings, Inc. (BPTH) Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias  
3/8/2013 8:55:43 AM

HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc. (OTCQX: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fifth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100-1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers, including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). The trial is being conducted at The University of Texas MD Anderson Cancer Center. Liposomal Grb-2 is systemically delivered by intravenous injection. In the fifth cohort, patients will receive a dose of 60 mg/m2 twice a week for four weeks, for a total of eight doses. As the Company reported in November, due to the favorable safety profile of Liposomal Grb-2, we have expanded the Phase I clinical trial to include higher dosages. Following the completion of the fifth cohort, Bio-Path expects to enroll patients into a sixth cohort with a dosage of 90 mg/ m2. The Company remains on track to complete dosing in the Phase I trial by mid-year 2013.
//-->